Protagenic Therapeutic -CW25PTIXWPreferred / convertible
13F holders, Q4 2024 (December 31)6holders +3
3new positions
0sold out
$0.00avg. 13F price*
At the end of Q4 2024, 6 institutions reported holding Protagenic Therapeutic -CW25 (PTIXW) in their 13F filings, up 3 from Q3 2024. 3 opened new positions and 0 sold out. The largest holders were Warberg Asset Management LLC ($1K), Susquehanna International Group, LLP ($302) and GTS Securities LLC ($76).
- Company
- Protagenic Therapeutic -CW25
- CUSIP
- 74365N111
- Latest filing quarter
- Q4 2025
History
Number of 13F holders
Total Exit/New Position Q3 2024 → Q4 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 3 | $62 |
| Exits | 0 | $0 |
All 13F filers, Q3 2024 → Q4 2024: 60,787 shares bought and 6,954 shares sold, net +53,833 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 6 holders
| Warberg Asset Management LLC | — | Reduce -3.9% | 170,242 | $1K |
| Susquehanna International Group, LLP | — | Add +44.1% | 67,173 | $302 |
| GTS Securities LLC | — | Add +0.4% | 25,400 | $76 |
| Two Sigma Securities, LLC | — | New | 17,500 | $61 |
| UBS Group AG | — | New | 360 | $1 |
| HRT Financial LP | — | New | 22,269 | $0 |
"% of holder's portfolio" is PTIXW's weight in each manager's 13F, not the share of Protagenic Therapeutic -CW25 the manager owns.